Fibroblast Growth Factor 18 (FGF18) Active Protein | FGF18 active protein

Active Fibroblast Growth Factor 18 (FGF18)

Cat. Num. AAA150332

• Applications: Activity Assay, Cell Culture
• Purity: >98%
• Synonyms: Fibroblast Growth Factor 18 (FGF18); N/A; Active Fibroblast Growth Factor 18 (FGF18); FGF18 active protein

• Host: E. coli
• Purity/Purification: >98%
• Form/Format: 20mM Tris, 150mM NaCl, pH8.0, containing 0.01% skl and 5% trehalose.

• Applicable Applications for FGF18 active protein: Activity Assay, Cell Culture
• Organism Species: Homo sapiens (Human)
• Source: Prokaryotic expression.
• Residues: Cys10~Arg199
• Tags: N-terminal His-tag
• Endotoxin Level: <1.0EU per 1ug (determined by the LAL method).
• Predicted isoelectric point: 9.9
• Usage: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
• Preparation and Storage: Storage:; Avoid repeated freeze/thaw cycles.; Store at 2-8 degree C for one month. ; Aliquot and store at -80 degree C for 12 months.; ; Stability Test:; The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 degree C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

WB (Western Blot)

(Western BlotSample: Recombinant FGF18, Human;Antibody: Rabbit Anti- Human FGF18 Ab)

SDS-PAGE

(SDS-PAGESample: Active recombinant FGF18, Human)

Bioactivity

(Fibroblast Growth Factor-18 (FGF18) is a trophic factor for mature chondrocytes and their progenitors. It has been reported to have significant anabolic effects on cartilage. FGF18 plays a central role in skeletal growth and development.Besides, Ly1 Antibody Reactive Homolog (LYAR) has been identified as an interactor of FGF18, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FGF18 and recombinant human LYAR. Briefly, FGF18 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100ul were then transferred to LYAR-coated microtiter wells and incubated for 2h at 37 degree C. Wells were washed with PBST and incubated for 1h with anti-FGF18 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37 degree C. Finally, add 50ul stop solution to the wells and read at 450nm immediately. The binding activity of FGF18 and LYAR was shown in Figure 1, and this effect was in a dose dependent manner.)

Sequence